nejm tirzepatide vs Semaglutide for Obesity – NEJM, May 2025 Relevant to endocrinology, internal medicine, cardiology, obesity medicine • Tirzepatide: −20.2% weight loss at 72 wks • Semaglutide: −13.7% • Greater waist reduction Tirzepatide as Compared with Semaglutide

They are about safety

Noom was previously offering microdoses of compounded GLP-1 semaglutide for weight loss for people with a BMI of 25 or higher

J., & Sluka, K

File File history File usage on Commons Metadata Original file (5,123 1,747 pixels, file size: 80 KB, MIME type: image/png) File information Structured data Captions Captions Add a one-line explanation of what this file represents I, the copyright holder of this work, hereby publish it under the following license: You are free: to share to copy, distribute and transmit the work to remix to adapt the work Under the following conditions: attribution You must give appropriate credit, provide a link to the license, and indicate if changes were made

This opens new avenues for PCa management, especially for patients with metabolic syndrome. The researchers highlighted that inflammation, a significant factor in cancer progression, is mitigated by GLP-1-RAs through their anti-inflammatory properties

Your Complete GLP-1 Diet Plan for Success You are going to be eating less when taking weight loss drugs (if they're doing their job!), so it becomes even more important to get the most out of every bite nutritionally